Description:

NSABP Protocol B-40 - Postoperative Adjuvant Treatments NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7DA758-8A3B-186C-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7DA758-8A3B-186C-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 12/18/14
  2. 1/9/15
  3. 7/5/15
Uploaded on:

July 5, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

NSABP Protocol B-40 - Postoperative Adjuvant Treatments NCT00408408

Submit every 6 months from date of randomization for the first 5 years; yearly thereafter, and when a protocol event occurs. Fax Form F to 412-622-2111

Header
Person Completing Form
Are data amended
Postoperative Radiation Therapy (RT)
Post-lumpectomy breast RT
Post-mastectomy chest wall RT
Regional nodal RT
Postoperative Systemic Adjuvant Therapy
Postoperative Adjuvant Hormonal Therapy
Postoperative Bevacizumab
Postoperative Trastuzumab
Postoperative Chemotherapy
Other

Similar models